Cerus Corporation (CERS)
CERS Stock Price Chart
Explore Cerus Corporation interactive price chart. Choose custom timeframes to analyze CERS price movements and trends.
CERS Company Profile
Discover essential business fundamentals and corporate details for Cerus Corporation (CERS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Devices
IPO Date
31 Jan 1997
Employees
614.00
Website
https://www.cerus.comCEO
William Greenman
Description
Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathogens in donated platelets and plasma. It also offers a dedicated INTERCEPT Blood System for the inactivation of harmful agents in red blood cell components. Furthermore, Cerus markets an INTERCEPT Blood System for Cryoprecipitation, which leverages its plasma technology to produce two key pathogen-reduced blood products: a cryoprecipitated fibrinogen complex for treating and controlling bleeding, particularly massive hemorrhages stemming from fibrinogen deficiency, and pathogen-reduced, cryoprecipitate-reduced plasma. Cerus distributes these platelet and plasma systems globally through a combination of its direct sales force and an extensive network of distributors, reaching markets in North America, Europe, the Commonwealth of Independent States, the Middle East, and Latin America. Established in 1991, Cerus Corporation maintains its corporate headquarters in Concord, California.
CERS Financial Timeline
Browse a chronological timeline of Cerus Corporation corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 30 Jul 2026
EPS estimate is -$0.01, while revenue estimate is $62.90m.
Earnings released on 30 Apr 2026
EPS came in at -$0.01 surpassing the estimated -$0.03 by +66.67%, while revenue for the quarter reached $59.90m , beating expectations by +7.58%.
Earnings released on 2 Mar 2026
EPS came in at -$0.01 matching the estimated -$0.01, while revenue for the quarter reached $64.60m , beating expectations by +4.48%.
Earnings released on 6 Nov 2025
EPS came in at -$0.00 surpassing the estimated -$0.02 by +99.50%, while revenue for the quarter reached $52.70m , missing expectations by -11.14%.
Earnings released on 5 Aug 2025
EPS came in at -$0.03 falling short of the estimated -$0.02 by -50.00%, while revenue for the quarter reached $52.45m , missing expectations by -3.38%.
Earnings released on 1 May 2025
EPS came in at -$0.04 surpassing the estimated -$0.05 by +20.00%, while revenue for the quarter reached $43.24m , missing expectations by -8.86%.
Earnings released on 20 Feb 2025
EPS came in at -$0.01 matching the estimated -$0.01, while revenue for the quarter reached $50.81m , missing expectations by -4.05%.
Earnings released on 30 Oct 2024
EPS came in at -$0.02 falling short of the estimated -$0.02 by -33.33%, while revenue for the quarter reached $46.02m , missing expectations by -9.21%.
Earnings released on 1 Aug 2024
EPS came in at -$0.03 falling short of the estimated -$0.02 by -25.00%, while revenue for the quarter reached $45.08m , missing expectations by -3.33%.
Earnings released on 2 May 2024
EPS came in at -$0.05 falling short of the estimated -$0.05 by -7.14%, while revenue for the quarter reached $38.37m , missing expectations by -6.75%.
Earnings released on 5 Mar 2024
EPS came in at -$0.01 falling short of the estimated -$0.01 by -58.23%, while revenue for the quarter reached $46.77m , missing expectations by -5.08%.
Earnings released on 2 Nov 2023
EPS came in at -$0.03 surpassing the estimated -$0.05 by +40.00%, while revenue for the quarter reached $39.77m , missing expectations by -22.35%.
Earnings released on 2 Aug 2023
EPS came in at -$0.07 falling short of the estimated -$0.05 by -40.00%, while revenue for the quarter reached $38.85m , missing expectations by -7.01%.
Earnings released on 4 May 2023
EPS came in at -$0.09 falling short of the estimated -$0.05 by -80.00%, while revenue for the quarter reached $30.97m , missing expectations by -11.07%.
Earnings released on 28 Feb 2023
EPS came in at -$0.08 falling short of the estimated -$0.05 by -68.42%, while revenue for the quarter reached $44.03m , missing expectations by -10.43%.
Earnings released on 3 Nov 2022
EPS came in at -$0.05 matching the estimated -$0.05, while revenue for the quarter reached $39.57m , missing expectations by -15.50%.
Earnings released on 4 Aug 2022
EPS came in at -$0.05 surpassing the estimated -$0.06 by +16.67%, while revenue for the quarter reached $41.00m , missing expectations by -10.88%.
Earnings released on 5 May 2022
EPS came in at -$0.07 surpassing the estimated -$0.10 by +30.00%, while revenue for the quarter reached $37.44m , missing expectations by -10.14%.
Earnings released on 22 Feb 2022
EPS came in at -$0.05 surpassing the estimated -$0.08 by +37.50%, while revenue for the quarter reached $39.87m , missing expectations by -9.18%.
Earnings released on 2 Nov 2021
EPS came in at -$0.07 surpassing the estimated -$0.10 by +30.00%, while revenue for the quarter reached $36.13m , missing expectations by -3.06%.
Earnings released on 3 Aug 2021
EPS came in at -$0.09 surpassing the estimated -$0.10 by +10.00%, while revenue for the quarter reached $31.48m , missing expectations by -16.63%.
CERS Stock Performance
Access detailed CERS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
